12,025 Shares in Masimo Corporation $MASI Purchased by Quantitative Investment Management LLC

Quantitative Investment Management LLC purchased a new stake in shares of Masimo Corporation (NASDAQ:MASI) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 12,025 shares of the medical equipment provider’s stock, valued at approximately $1,774,000.

Several other hedge funds have also bought and sold shares of MASI. Invesco Ltd. increased its stake in shares of Masimo by 35.4% during the third quarter. Invesco Ltd. now owns 321,363 shares of the medical equipment provider’s stock valued at $47,417,000 after purchasing an additional 84,060 shares in the last quarter. UBS Group AG boosted its position in shares of Masimo by 19.4% in the 3rd quarter. UBS Group AG now owns 169,800 shares of the medical equipment provider’s stock worth $25,054,000 after purchasing an additional 27,636 shares in the last quarter. Capital Fund Management S.A. purchased a new stake in shares of Masimo in the 3rd quarter worth approximately $5,079,000. BNP Paribas Financial Markets grew its stake in shares of Masimo by 223.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,507 shares of the medical equipment provider’s stock worth $2,141,000 after buying an additional 10,024 shares during the last quarter. Finally, Fieldview Capital Management LLC bought a new position in Masimo during the 3rd quarter valued at approximately $1,005,000. Institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the subject of a number of recent research reports. Bank of America assumed coverage on Masimo in a research note on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective for the company. Wolfe Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Thursday, January 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Monday, December 1st. Finally, Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Masimo presently has a consensus rating of “Hold” and an average price target of $181.17.

Masimo Stock Performance

Shares of MASI opened at $175.50 on Friday. The company has a market cap of $9.43 billion, a price-to-earnings ratio of -16.65, a P/E/G ratio of 1.78 and a beta of 1.21. The business’s fifty day simple moving average is $150.84 and its two-hundred day simple moving average is $145.65. Masimo Corporation has a 12 month low of $125.94 and a 12 month high of $175.90. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.